Many promising results have been published using the CRISPR/Cas9 technology to efficiently correct mutations in epidermolysis bullosa, especially for mutations in COL7A1 [24,30,31,32,33,34], COL17A1 [35,36], KRT5 [37] and KRT14 [38]. This evidence concerns the gene COL17A1 and epidermolysis bullosa.